Previous 10 | Next 10 |
Twist Bioscience (TWST): FQ1 GAAP EPS of -$0.72 beats by $0.01.Revenue of $28.2M (+64.3% Y/Y) beats by $1.82M.Press Release For further details see: Twist Bioscience EPS beats by $0.01, beats on revenue
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2021 ended December 31, 2020. ...
Twist Bioscience (NASDAQ:TWST) is scheduled to announce FQ1 earnings results on Thursday, February 4th, after market close.The consensus EPS Estimate is -$0.78 (+22.0% Y/Y) and the consensus Revenue Estimate is $26.38M (+53.7% Y/Y).Over the last 3 months, EPS estimates have seen 1 upward revi...
[[AINV]], [[ATVI]], [[BHE]], [[BILL]], [[COLM]], [[CPT]], [[CSL]], [[DECK]], [[DLX]], [[DXC]], [[ENVA]], [[ESS]], [[EXPO]], [[F]], [[FLT]], [[FTNT]], [[FTV]], [[GILD]], [[GPRO]], [[HIG]], [[HUBG]], [[KN]], [[LESL]], [[LGF.A]], [[LPLA]], [[MCHP]], [[MPWR]], [[MSI]], [[MTD]], [[MTX]], [[NBIX]],...
-- Team Promotions and Appointments Reflect Corporate Growth -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced several senior management promotion...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2021 first quarter ended December 31, 2020, followi...
Biotechnology companies that specialize in niche segments like genomics, cell-technology and genetic analysis are likely to see major upside in their stocks in the near-term. With increasing numbers of studies and advanced research, these companies are set to achieve major milestones. 10X GEN...
When the market is in a phase of rich valuation, it is tempting to broadly identify the market or these stocks as “overvalued”. Making the distinction between stocks deserving high valuations and those that are overvalued is key, particularly in the current market. T...
Familiar names topped ARK Investment Management's actively-managed ETFs last quarter, while work-from-home stocks pulled down performance as enthusiasm for recovery stocks arrived with vaccine approvals.And in her note about Q4 performance, ARK CEO Cathie Wood said it looks like cyclical sect...
Gainers: [[MDLY]] +66.7%. [[KODK]] +13.5%. [[MDLX]] +12.2%. [[IDN]] +12.1%. [[OCX]] +11.7%.Losers: [[INO]] -8.5%. [[NTN]] -6.4%. [[TWST]] -5.8%. [[YQ]] -4.2%. [[ORC]] -4.2%. For further details see: MDLY, KODK, NTN and INO among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...